Blood Cancer
Haematology
Haematology is the study of blood, blood diseases, and blood-forming tissues and organs. Haematologists focus on the diagnosis, treatment and prevention of blood-related disorders and malignancies. They also focus on diseases of the bone marrow and lymphatic organs such as the lymph node, thymus, spleen, and tonsils which are fed by blood cells and are crucial for the body’s immune response.
For over three decades, Janssen has dedicated itself to advancing research and solutions to meet the needs of people with haematological malignancies. Our goal is to not only make blood-related conditions treatable, but ultimately preventable and curable.
Explore our Disease Areas
Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma is an aggressive type of blood cancer that develops in the outer part of the lymph node, an essential part of the immune system. Affecting only 1 in 100,000 people, MCL is a very rare cancer.
Amyloidosis
Amyloidosis occurs when the body begins to make a protein differently than it did before and is no longer able to absorb that protein. There are several types of Amyloidosis, the four most common of which are: Amyloid light-chain (AL) Amyloidosis, Amyloid A (AA) Amyloidosis, Hereditary Amyloidosis, and Wild-type Amyloidosis.
Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukaemia is a slow-growing cancer of the blood and bone marrow, which results in incompetent, small white blood cells that compromise the immune system. CLL is one of the most common types of leukaemia in Western countries, accounting for 25% of all diagnoses. There are instances in which CLL is used as an overarching term that includes Small Lymphocytic Lymphoma (SLL) because they are both nearly the same disease, however CLL is commonly detected in the blood and bone marrow, whereas SLL is primarily detected in the lymph nodes.
Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes are a group of rare, slow-growing blood disorders in which blood cells are misprinted, making them unable to do their job properly.8 MDS subtypes are categorized by the specific type of blood cell affected and vary in rarity.9
Marginal Zone Lymphoma (MZL)
Marginal Zone Lymphoma is a slow-growing blood cancer that develops in the marginal zones of the lymphatic tissue, a key part of our immune system.10 It’s a rare cancer that has three subtypes: Mucosa-Associated Lymphoid Tissue (MALT), Nodal Marginal Zone B-cell Lymphoma (NMZL) and Splenic Marginal Zone B-cell Lymphoma (SMZL).
المراجع
[1]
Myeloma UK. Myeloma: an introduction. Available at: https://www.myeloma.org.uk/wp-content/uploads/2018/03/Myeloma-UK-Myeloma-An-Introduction-1.pdf Last accessed April 2021.
[2]
International Myeloma Foundation. Concise review of the disease and treatment options. 2017 edition. Available at: https://imf-d8-prod.s3.us-west-1.wasabisys.com/resource/ConciseReview.pdf Last accessed April 2021.
[3]
Memorial Sloan Kettering Cancer Center. Multiple Myeloma Symptoms. https://www.mskcc.org/cancer-care/types/multiple-myeloma/multiple-myeloma-symptoms Last accessed April 2021.
[4]
Myeloma Patients Europe. Multiple Myeloma – A Patients’ Guide. Available at: www.mpeurope.org/files/ Patients-guide-mpe-web-version-V2.pdf. Last accessed Aug 2018.
[5]
International Myeloma Foundation. Understanding MGUS and Smoldering Multiple Myeloma, and Active Myeloma. Last Accessed: September 2021. Available at: https://www.myeloma.org/what-are-mgus-smm-mm
[6]
International Myeloma Foundation. Concise review of the disease and treatment options. 2017 edition. Available at: https://imf-d8-prod.s3.us-west-1.wasabisys.com/resource/ConciseReview.pdf Last accessed April 2021.
[7]
Moreau P, et al. Ann Oncol. 2017;28 (Suppl 4):iv52-iv61